Ignite Creation Date:
2024-05-05 @ 11:59 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00192374
Status:
COMPLETED
Last Update Posted:
2006-10-03
First Post:
2005-09-12
Brief Title:
Trial to Compare the Safety Tolerability Immunogenicity and Efficacy of Three Dose Levels of a Liquid Formulation of Influenza Virus Vaccine CAIV-T in Healthy Children
Sponsor:
MedImmune LLC
Organization:
MedImmune LLC
Study Overview
Official Title:
A Prospective Randomized Double-Blind Placebo-Controlled Phase III Multicenter Trial to Compare the Safety Tolerability Immunogenicity and Efficacy of Three Dose Levels of a Liquid Formulation of Influenza Virus Vaccine Trivalent Types A BLive Cold-Adapted CAIV-T in Healthy Children
Status:
COMPLETED
Status Verified Date:
2006-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
- Trial to Compare the Safety Tolerability Immunogenicity and Efficacy of Three Dose Levels of a Liquid Formulation ofCAIV-T in Healthy Children
Detailed Description:
- A Prospective Randomized Double-Blind Placebo-Controlled Phase III Multicenter Trial to Compare the Safety Tolerability Immunogenicity and Efficacy of Three Dose Levels of a Liquid Formulation of Influenza Virus Vaccine Trivalent Types A B Live Cold-Adapted CAIV-T in Healthy Children
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None